CAPR CAPRICOR THERAPEUTICS, INC.

Nasdaq capricor.com


$ 6.69 $ 0.00 (0 %)    

Thursday, 16-Oct-2025 07:03:31 EDT
QQQ $ 605.68 $ 0.00 (0 %)
DIA $ 464.10 $ 0.00 (0 %)
SPY $ 667.84 $ 0.00 (0 %)
TLT $ 90.80 $ 0.00 (0 %)
GLD $ 390.47 $ 0.00 (0 %)
$ 6.69
$ 6.72
$ 6.69 x 18
$ 6.75 x 500
-- - --
$ 5.68 - $ 22.90
941,747
na
305.85M
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-17-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-11-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-29-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-22-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-24-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ: CAPR) with a Buy and maintains $2...

 why-capricor-therapeutics-stock-is-surging-today

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its r...

 capricor-issues-bla-update-for-dmd-cell-therapy-deramiocel-following-fda-type-a-meeting-post-crl-hope-3-pivotal-trial-topline-data-expected-mid-q4-2025-to-support-bla-resubmission

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025...

 hc-wainwright--co-reiterates-buy-on-capricor-therapeutics-maintains-24-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $24...

 capricor-therapeutics-files-for-mixed-shelf-offering-of-up-to-300m

- SEC Filing

 capricor-responds-to-fdas-unexpected-public-release-of-crl-for-duchenne-cell-therapy-will-publish-its-rebuttal-online-for-transparency

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...

 4-biotech-stocks-that-are-showing-weakness-momentum-scores-fading-over-the-past-week

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stoc...

 biohaven-advances-toward-potential-first-fda-approved-therapy-for-spinocerebellar-ataxia-fda-drops-advisory-meeting

Biohaven shares rise as FDA removes advisory committee meeting for troriluzole in spinocerebellar ataxia, with decision expecte...

 capricor-therapeutics-announces-first-subjects-dosed-in-phase-1-clinical-trial-evaluating-its-stealthx-exosome-based-vaccine

First-in-human trial of Capricor's StealthX™ vaccine initiated under HHS's Project NextGenTrial conducted and funded by...

 capricor-therapeutics-q2-eps-057-misses-046-estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate ...

 whats-going-on-with-sarepta-capricor-and-other-gene-therapy-stocks-on-wednesday

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controve...

 capricor-therapeutics-to-host-july-29-webinar-with-ppmd-on-deramiocel-bla-progress-and-cardiomyopathy-in-duchenne-muscular-dystrophy

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...

 roth-capital-maintains-buy-on-capricor-therapeutics-lowers-price-target-to-12

Roth Capital analyst Boobalan Pachaiyappan maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and lowers the price tar...

 hc-wainwright--co-maintains-buy-on-capricor-therapeutics-lowers-price-target-to-24

HC Wainwright & Co. analyst Joseph Pantginis maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and lowers the pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION